TY - JOUR
T1 - Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases
AU - Mimori, K.
AU - Ogawa, K.
AU - Okamoto, M.
AU - Sudo, T.
AU - Inoue, H.
AU - Mori, M.
N1 - Funding Information:
We would like to extend a special appreciation to Ms. Mayumi Oda for her technique of Lightcycler PCR. The present study was supported by the grant sponsor; Japan Society for the Promotion of Science, a Grant-in-Aid for Scientific Research (B) (15390398, 15390379, 16390381), a Grant-in-Aid for Scientific Research (C) (15591412, 15591411).
PY - 2005/5
Y1 - 2005/5
N2 - Introduction. Enhancer of zeste homolog 2 (EZH-2) is a polycomb group (PcG) protein, and the clinical significance of this protein has not yet been determined in colorectal cancer (CRC) cases. Recently, investigations of CRC cases have focused on the interaction between EZH-2 and histone deacetylase-1 (HDAC-1). Patients and methods. We performed real time RT-PCR to evaluate the expression of EZH-2 mRNA quantitatively in tumour and normal tissue samples from 61 cases of CRC. The expression of HDAC-1 in CRC cases was also examined in order to compare its levels with those of EZH-2. Results. Among the CRC cases, 32 patients whose tumour tissue showed overexpression of EZH-2 also had a significantly worse prognosis than did 29 patients whose tumour tissue showed low EZH-2 expression (p<0.05). In addition, a significant correlation between EZH-2 and HDAC-1 expression was observed in 61 CRC cases (p<0.05). Moreover, 20 cases of both high EZH-2 and high HDAC-1 expression showed poor prognoses than did 19 cases in which there was low EZH-2 and low HDAC-1 expression (p<0.05). Conclusion. The abundant expression of EZH-2 in CRC cases indicated that EZH-2 may be an oncogene and a prognostic marker for CRC cases. We discovered there was concordant expression of HDAC-1 with EZH-2 in clinical CRC cases, in addition to the fact that higher expression levels of both genes predicted a poor prognosis.
AB - Introduction. Enhancer of zeste homolog 2 (EZH-2) is a polycomb group (PcG) protein, and the clinical significance of this protein has not yet been determined in colorectal cancer (CRC) cases. Recently, investigations of CRC cases have focused on the interaction between EZH-2 and histone deacetylase-1 (HDAC-1). Patients and methods. We performed real time RT-PCR to evaluate the expression of EZH-2 mRNA quantitatively in tumour and normal tissue samples from 61 cases of CRC. The expression of HDAC-1 in CRC cases was also examined in order to compare its levels with those of EZH-2. Results. Among the CRC cases, 32 patients whose tumour tissue showed overexpression of EZH-2 also had a significantly worse prognosis than did 29 patients whose tumour tissue showed low EZH-2 expression (p<0.05). In addition, a significant correlation between EZH-2 and HDAC-1 expression was observed in 61 CRC cases (p<0.05). Moreover, 20 cases of both high EZH-2 and high HDAC-1 expression showed poor prognoses than did 19 cases in which there was low EZH-2 and low HDAC-1 expression (p<0.05). Conclusion. The abundant expression of EZH-2 in CRC cases indicated that EZH-2 may be an oncogene and a prognostic marker for CRC cases. We discovered there was concordant expression of HDAC-1 with EZH-2 in clinical CRC cases, in addition to the fact that higher expression levels of both genes predicted a poor prognosis.
UR - http://www.scopus.com/inward/record.url?scp=17144412566&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17144412566&partnerID=8YFLogxK
U2 - 10.1016/j.ejso.2004.11.001
DO - 10.1016/j.ejso.2004.11.001
M3 - Article
C2 - 15837043
AN - SCOPUS:17144412566
SN - 0748-7983
VL - 31
SP - 376
EP - 380
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
IS - 4
ER -
